Extramedullary involvement (or extramedullary disease, EMD) represents an aggressive
form of multiple myeloma (MM), characterized by the ability of a clone and/or subclone to …

The treatment of multiple myeloma (MM) continues to evolve rapidly with arrival of multiple
new drugs, and emerging data from randomized trials to guide therapy. Along the disease …

Background Daratumumab, a monoclonal antibody targeting CD38, has been approved for
use with standard myeloma regimens. An evaluation of subcutaneous daratumumab …

Elranatamab is a humanized B-cell maturation antigen (BCMA)-CD3 bispecific antibody. In
the ongoing phase 2 MagnetisMM-3 trial, patients with relapsed or refractory multiple …

Background Survival is poor among patients with triple-class–exposed relapsed and
refractory multiple myeloma. Idecabtagene vicleucel (ide-cel), a B-cell maturation antigen …

ALLO-715 is a first-in-class, allogeneic, anti-BCMA CAR T cell therapy engineered to
abrogate graft-versus-host disease and minimize CAR T rejection. We evaluated escalating …

Abstract Disease Overview Multiple myeloma accounts for approximately 10% of
hematologic malignancies. Diagnosis The diagnosis requires≥ 10% clonal bone marrow …

Background Teclistamab is a T-cell–redirecting bispecific antibody that targets both CD3
expressed on the surface of T cells and B-cell maturation antigen expressed on the surface …

Background B-cell maturation antigen (BCMA)–directed chimeric antigen receptor (CAR) T-
cell therapies have generated responses in patients with advanced myeloma, but relapses …

PURPOSE CARTITUDE-1, a phase Ib/II study evaluating the safety and efficacy of
ciltacabtagene autoleucel (cilta-cel) in heavily pretreated patients with relapsed/refractory …